Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for assaying lower respiratory tract infection or inflammation

a technology of infection or inflammation, applied in the field of prognosis or survival prediction and/or diagnosis of infections or inflammatory diseases of the airways and lungs, can solve the problem that none of these biomarkers is completely satisfying, and achieve the effect of high levels of psp/reg

Inactive Publication Date: 2013-03-28
UNIV HOSPITAL OF BASEL
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a way to predict and diagnose infections and inflammation in the lungs, particularly in patients with chronic obstructive pulmonary disease (COPD). The method involves measuring a protein called PSP / reg in a fluid sample from the body. High levels of this protein indicate the development and severity of lower respiratory tract infections, such as COPD or ventilator-acquired pneumonia. The method can also predict survival in ventilator-acquired pneumonia and help detect COPD patients with positive sputum microbiology.

Problems solved by technology

Detecting the presence, defining the cause, and predicting the severity of lower respiratory tract infections are constant challenges for the treating clinician.
Unfortunately, none of these biomarkers is completely satisfying.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for assaying lower respiratory tract infection or inflammation
  • Method for assaying lower respiratory tract infection or inflammation
  • Method for assaying lower respiratory tract infection or inflammation

Examples

Experimental program
Comparison scheme
Effect test

example 1

PSP / reg is a Suitable Marker to Assess Disease Severity and Stratify Risk in VAP

[0055]It has been investigated whether PSP / reg is predictive for survival in ventilator associated pneumonia.

Test Patients

[0056]The study included 101 patients (mean age, 56 years) with clinically diagnosed VAP. Patients deceased within 28 days were classified as non-survivors (NS). PSP / reg levels and sequential organ failure assessment (SOFA) scores were obtained on the day of VAP-onset and for 10 consecutive days. Detailed baseline characteristics for survivors and non-survivors are summarized in Table 1. Despite high antibiotic pre-treatment within 14 days prior to study inclusion (75%), respiratory specimens identified a causative organism in 74 patients (76%). The most frequent pathogens were Staphylococcus aureus (30%), Pseudomonas aeruginosa (25%) and Klebsiella species (13%). Appropriate initial antibiotic therapy, defined as a regimen combining an aminoglycoside or a fluoroquinolone plus a betal...

example 2

PSP / reg is Increased in Acute Exacerbations of COPD with Positive Sputum Culture

[0063]It has been investigated whether serum and plasma PSP / reg is increased in acute exacerbations of COPD and whether PSP / reg detects positive sputum in COPD.

Test Patients

[0064]200 patients admitted to hospital for acute exacerbation of COPD were examined and were followed up for 2 years. The short and long term follow-up visits were performed 14-18 days, 6 months and 2 years after hospital admission, and comprised clinical, laboratory and lung function assessments. Clinical outcome data were obtained from medical records from hospital admission and family physicians. Patients were classified as clinical success or clinical failure. Clinical failure was defined by the occurrence of an exacerbation of COPD requiring hospitalisation or death of any cause. For survival analysis all patients were classified as survivors or non-survivors after two year follow-up. All cause mortality was assessed at 6 months...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Densityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a reliable method of prediction of lower respiratory tract infection or inflammation in humans, wherein the level of pancreatic stone protein / regenerating protein (PSP / reg) is determined in serum, and a high level is indicative of the development and the severity of the disease, allowing the classification of patients according to risk.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a method of prognosis or survival prediction and / or diagnosis of infections or inflammatory diseases of the airways and lungs, in particular for prognosis of the development of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) or ventilator associated pneumonia (VAP). The invention allows for the determination of the level of pancreatic stone protein / regenerating protein (PSP / reg) in body fluid samples of a patient and sorting patients according to risk.BACKGROUND OF THE INVENTION[0002]Lower respiratory tract infections, i.e. acute bronchitis, acute exacerbations of chronic obstructive pulmonary disease (COPD) or pneumonia, account for almost 10% of the worldwide burden of morbidity and mortality. Detecting the presence, defining the cause, and predicting the severity of lower respiratory tract infections are constant challenges for the treating clinician. Among the most commonly used biomarkers for the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/58
CPCG01N33/6893G01N33/581G01N2800/122G01N2800/12G01N2333/47
Inventor STOLZ, DAIANALAJAUNIAS, FREDERIC
Owner UNIV HOSPITAL OF BASEL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com